About this policy
This policy addresses the off-labeled use of rituximab for non-anti-neoplastic conditions. The following are comments received during open comment period February 11, 2021 thru March 28, 2021 for DL38920 Off-label Use of Rituximab abd Rituximab Biosimiliars. The policy iswill be in notice effective June 24, 2021, 2021 and become effective August 8, 2021.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.